| Clinical data | |
|---|---|
| Trade names | Obizur |
| Other names | Antihemophilic factor (recombinant) |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category | |
| Drug class | Antihemophilic factor |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
Susoctocog alfa, sold under the brand nameObizur, is amedication used for the treatment of bleeding episodes in adults with acquiredhaemophilia, a bleeding disorder caused by the spontaneous development of antibodies that inactivatefactor VIII.[6][5][7]
Susoctocog alfa was approved for medical use in the United States in October 2014,[8][9] and for medical use in the European Union in November 2015.[6]
Factor VIII is one of the proteins needed for normal clotting of the blood.[6]
 | Thisdrug article relating to theblood andblood forming organs is astub. You can help Wikipedia byadding missing information. |
